Compare AbbVie Inc (ABBV) vs Western Union Co (WU) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

Western Union (WU) trades at $7.95, down 0.75% on the day, with mixed technical signals but a bullish overall trend. The stock shows strong profitability with a 10.88% net margin and 47.66% ROE, and valuation metrics like a P/E of 5.87 and P/S of 0.63 appear attractive. Recent developments include a partnership with Total Wireless for fee-free money transfers and progress on the Intermex acquisition, signaling digital expansion. However, Q1 2026 earnings missed expectations, and the company faces a high debt load with a debt-to-asset ratio of 34.64% as of 2025.

The outlook for WU is cautiously optimistic, with potential upside from digital growth initiatives and a high dividend yield, but risks include competitive pressures, recent earnings volatility, and significant leverage. Analyst sentiment is mixed, with a majority Hold rating, reflecting balanced views on growth prospects versus financial constraints.